法舒地尔治疗肺心病的临床疗效及对血hs-CRP、NT-proBNP的影响
|
摘要
目的探讨法舒地尔治疗肺心病的临床疗效以及对患者血hs-CRP、NT-proBNP的影响。方法选取2015年2月至2016年3月在我院接受治疗的肺心病患者90例,采用随机数表法将患者分为观察组和对照组,每组均为45例,观察组患者给予法舒地尔治疗,对照组患者给予常规治疗,观察两组患者治疗前后心功能指标、肺功能指标以及hs-CRP、NT-proBNP以及肺动脉收缩压等指标改善情况,同时比较两组患者治疗后的临床疗效。结果治疗后,两组患者的hs-CRP以及NT-proBNP表达水平都有所降低,观察组(19.12±3.89ng/L、45.23±10.25ng/L)低于对照组(25.12±4.02ng/L、56.12±9.89ng/L),两组比较差异显著(P<0.05);治疗后,两组患者的LVEF表达水平均有升高,观察组高于对照组,两组比较差异显著(P<0.05);治疗后,观察组患者的LVEDD以及LAD表达水平都有降低,且低于对照组,两组比较差异显著(P<0.05);治疗后,两组患者的SaO_2都有所升高,观察组高于对照组,具有统计学意义(P<0.05);治疗后,观察组患者的肺动脉收缩压有所降低且低于对照组,两组比较差异显著(P<0.05);治疗后,观察组患者的PaO_2水平表达(78.23±12.02mmHg)高于对照组(65.89±11.45mmHg),PaCO_2水平表达(56.12±8.23mmHg)低于对照组(63.89±8.12mmHg),两组比较差异显著(P<0.05);观察组患者治疗后的总有效率为95.56%高于对照组75.56%,两组比较差异显著(P<0.05)。结论给予肺心病患者法舒地尔治疗,能够有效改善患者的临床疗效,同时也能够显著降低患者的hs-CRP以及NT-proBNP的水平表达,值得临床推广使用。
Objective To investigate the clinical efficacy of fasudil in treatment of pulmonary heart disease and its effect on blood hs-CRP and NT-proBNP. Methods 90 patients with pulmonary heart disease from February2015 to March 2016 in our hospital were randomly were randomly divided into observation group and control group,and each group had 45 cases. The observation group was treated with fasudil,and the control group was given routine treatment. Their cardiac function index,pulmonary function,hs-CRP,NT-proBNP,and the index of pulmonary artery systolic pressure and other indicators were compared between the two groups before and after treatment. Results After treatment,the levels of hs-CRP and NT-proBNP decreased,and they were( 19. 12 ± 3. 89 ng/L,45. 23 ±10. 25 ng/L) in the observation group and( 25. 12 ± 4. 02 ng/L,56. 12 ± 9. 89 ng/L) in the control group( P <0. 05). The expression of LVEF was elevated,and it was higher in the observation group than in the control group( P< 0. 05). The expression of LVEDD and LAD decreased in the observation group,and it was obviously lower than that in the control group( P < 0. 05). The value of SaO_2 increased in the two groups,and the observation group was statistically higher than the control group( P < 0. 05). Their pulmonary artery systolic pressure decreased in the two groups,and it was lower in the observation group than in the control group( P < 0. 05). The levels of PaO_2 and PaCO_2 were( 78. 23 ± 12. 02 mmHg) and( 56. 12 ± 8. 23 mmHg) in the observation group and( 65. 89 ±11. 45 mmHg) and( 63. 89 ± 8. 12 mmHg) in the control group( P < 0. 05). The total effective rate was 95. 56% in the observation group,which was obviously higher than 75. 56% in the control group( P < 0. 05). Conclusion Fasudil can effectively improve their clinical effect,and reduce hs-CRP and NT-proBNP expression in treatment of pulmonary heart disease patients,which is worthy of widely clinical application.
Objective To investigate the clinical efficacy of fasudil in treatment of pulmonary heart disease and its effect on blood hs-CRP and NT-proBNP. Methods 90 patients with pulmonary heart disease from February2015 to March 2016 in our hospital were randomly were randomly divided into observation group and control group,and each group had 45 cases. The observation group was treated with fasudil,and the control group was given routine treatment. Their cardiac function index,pulmonary function,hs-CRP,NT-proBNP,and the index of pulmonary artery systolic pressure and other indicators were compared between the two groups before and after treatment. Results After treatment,the levels of hs-CRP and NT-proBNP decreased,and they were( 19. 12 ± 3. 89 ng/L,45. 23 ±10. 25 ng/L) in the observation group and( 25. 12 ± 4. 02 ng/L,56. 12 ± 9. 89 ng/L) in the control group( P <0. 05). The expression of LVEF was elevated,and it was higher in the observation group than in the control group( P< 0. 05). The expression of LVEDD and LAD decreased in the observation group,and it was obviously lower than that in the control group( P < 0. 05). The value of SaO_2 increased in the two groups,and the observation group was statistically higher than the control group( P < 0. 05). Their pulmonary artery systolic pressure decreased in the two groups,and it was lower in the observation group than in the control group( P < 0. 05). The levels of PaO_2 and PaCO_2 were( 78. 23 ± 12. 02 mmHg) and( 56. 12 ± 8. 23 mmHg) in the observation group and( 65. 89 ±11. 45 mmHg) and( 63. 89 ± 8. 12 mmHg) in the control group( P < 0. 05). The total effective rate was 95. 56% in the observation group,which was obviously higher than 75. 56% in the control group( P < 0. 05). Conclusion Fasudil can effectively improve their clinical effect,and reduce hs-CRP and NT-proBNP expression in treatment of pulmonary heart disease patients,which is worthy of widely clinical application.
引文
[1]刘静.血浆脑钠肽和超敏C反应蛋白与肺心病心力衰竭患者心功能关系的研究[J].中国医药科学,2015,5(8):129-131.
[2]伏攀,李春碧.超敏C反应蛋白和脑钠肽检测在慢性阻塞性肺疾病并发肺心病中的临床意义[J].实用临床医药杂志,2015,19(1):29-31,48.
[3]肖祖华,钟德福,欧次高,等.慢性阻塞性肺疾病并肺心病患者与hs-CRP、NT-pro BNP相关性研究[J].医学检验与临床,2015,26(2):27-29.
[4]卜丽娜,宋爱玲,贾卫红,等.法舒地尔治疗老年慢性肺源性心脏病临床疗效及其机制的随机对照研究[J].中国全科医学,2017,20(5):538-542.
[5]邢鹏程,马可,李利娟,等.比索洛尔治疗老年慢性阻塞性肺病急性加重并肺心病患者的疗效及对心功能、hs-CRP、NTpro BNP水平的影响[J].中国老年学杂志,2015,35(20):5845-5847.
[6]常湘辉,李秀萍,陈梅,等.慢性肺心病急性加重期患者动脉血气NT-pro BNP与hs-CRP的研究[J].宁夏医学杂志,2015,37(10):890-892.
[7]Secchi F,Resta EC,CannaòPM,et al.Four-year cardiac magnetic resonance(CMR)follow-up of patients treated with percutaneous pulmonary valve stent implantation[J].Eur Radiol,2015,25(12):3606-3613.
[8]易小莉,余秋影.慢性阻塞性肺疾病并肺心病患者与超敏C-反应蛋白、N端前脑钠肽相关性研究[J].黑龙江医学,2017,41(1):57-58.
[9]黄刚.慢阻肺合并肺心病心力衰竭患者心功能与其血清炎性细胞因子、BNP的相关性研究[J].北方药学,2015,12(4):106-107.
[10]王福琴,刘永娟,刘政,等.芪苈强心胶囊对老年慢性阻塞性肺疾病急性加重致中重度肺心病患者的短期疗效观察[J].中国中西医结合急救杂志,2016,23(2):175-177.
[11]金晓辉,朱虹燕.瑞舒伐他汀对慢性阻塞性肺疾病合并肺心病患者炎性因子及免疫功能的影响[J].中国基层医药,2017,24(6):861-865.
[12]周建伟,赵军,车向京,等.重组人脑利钠肽联合低分子肝素钙对重症肺心病心力衰竭患者炎性细胞因子的影响[J].现代中西医结合杂志,2016,25(14):1565-1567.
[13]Hou Y,Sun DD,Yuan LJ,et al.Clinical Application of Superior Vena Cava Spectra in Evaluation of Pulmonary Hypertension:A Comparative Echocardiography and Catheterization Study[J].Ultrasound Med Biol,2016,42(1):110-117.
[14]徐志伟,赵文强,程志祥.慢性肺源性心脏病患者血N末端B型钠尿肽和超敏C反应蛋白水平的临床意义[J/CD].中西医结合心血管病电子杂志,2015,3(33):69-70,72.
[15]赖蓉,李多,兰四友,等.法舒地尔联合无创正压通气治疗慢性肺源性心脏病急性加重的临床价值[J].中国现代医学杂志,2016,26(2):55-59.
[16]丁明霞,卢丹,常媛媛,等.低分子肝素治疗老年慢性阻塞性肺疾病合并肺心病急性发作期效果[J].临床肺科杂志,2015,20(3):487-489.
[17]王建雄,谢言秋,彭沪,等.丹参酮ⅡA磺酸钠注射液治疗老年肺源性心脏病患者的临床观察[J].中华老年心脑血管病杂志,2015,17(5):532-533.
[18]苟连平,刘世平,方志远.心脑欣丸对肺心病合并冠心病患者CAT评分及心肺功能、血液流变学的影响[J].中国药房,2016,27(20):2810-2813.
[19]邓俊,邓欢,冯健,等.氯沙坦与环磷腺苷葡胺联合治疗对肺心病患者肺功能与免疫功能的影响[J].中国老年学杂志,2016,36(8):1915-1917.
[20]胡晓冬,顾培洁.益气补肾化痰祛瘀法在改善缓解期慢性阻塞性肺疾病合并肺心病患者生存质量中的应用[J].湖北中医药大学学报,2015,17(4):55-57.
[21]Selman L,Mc Dermott K,Donesky D,et al.Appropriateness and acceptability of a Tele-Yoga intervention for people with heart failure and chronic obstructive pulmonary disease:qualitative findings from a controlled pilot study[J].BMC Complement Altern Med,2015,15:21.
[22]杜宋耿,陈德俊,陈尊发.低分子肝素钠注射液对肺心病患者纤维蛋白原、血小板颗粒膜蛋白和D-二聚体的影响[J].疑难病杂志,2015,14(3):230-232.
[23]袁连方,戴璇.红花黄色素对肺心病患者血小板CD62P表达、血浆D-dimer水平的影响及意义[J].山东医药,2015,55(28):86-87.
[24]郑咏仪,郑国雄,杨陪.老年充血性心衰与肺心病患者动脉血气和N末端脑钠肽及血小板参数的变化及意义[J].中国老年学杂志,2015,35(14):3898-3899.
[25]孙晓坤.应用Bi PAP无创呼吸机治疗肺心病并发Ⅱ型呼吸衰竭的临床效果观察[J].临床肺科杂志,2015,20(3):550-552.
[2]伏攀,李春碧.超敏C反应蛋白和脑钠肽检测在慢性阻塞性肺疾病并发肺心病中的临床意义[J].实用临床医药杂志,2015,19(1):29-31,48.
[3]肖祖华,钟德福,欧次高,等.慢性阻塞性肺疾病并肺心病患者与hs-CRP、NT-pro BNP相关性研究[J].医学检验与临床,2015,26(2):27-29.
[4]卜丽娜,宋爱玲,贾卫红,等.法舒地尔治疗老年慢性肺源性心脏病临床疗效及其机制的随机对照研究[J].中国全科医学,2017,20(5):538-542.
[5]邢鹏程,马可,李利娟,等.比索洛尔治疗老年慢性阻塞性肺病急性加重并肺心病患者的疗效及对心功能、hs-CRP、NTpro BNP水平的影响[J].中国老年学杂志,2015,35(20):5845-5847.
[6]常湘辉,李秀萍,陈梅,等.慢性肺心病急性加重期患者动脉血气NT-pro BNP与hs-CRP的研究[J].宁夏医学杂志,2015,37(10):890-892.
[7]Secchi F,Resta EC,CannaòPM,et al.Four-year cardiac magnetic resonance(CMR)follow-up of patients treated with percutaneous pulmonary valve stent implantation[J].Eur Radiol,2015,25(12):3606-3613.
[8]易小莉,余秋影.慢性阻塞性肺疾病并肺心病患者与超敏C-反应蛋白、N端前脑钠肽相关性研究[J].黑龙江医学,2017,41(1):57-58.
[9]黄刚.慢阻肺合并肺心病心力衰竭患者心功能与其血清炎性细胞因子、BNP的相关性研究[J].北方药学,2015,12(4):106-107.
[10]王福琴,刘永娟,刘政,等.芪苈强心胶囊对老年慢性阻塞性肺疾病急性加重致中重度肺心病患者的短期疗效观察[J].中国中西医结合急救杂志,2016,23(2):175-177.
[11]金晓辉,朱虹燕.瑞舒伐他汀对慢性阻塞性肺疾病合并肺心病患者炎性因子及免疫功能的影响[J].中国基层医药,2017,24(6):861-865.
[12]周建伟,赵军,车向京,等.重组人脑利钠肽联合低分子肝素钙对重症肺心病心力衰竭患者炎性细胞因子的影响[J].现代中西医结合杂志,2016,25(14):1565-1567.
[13]Hou Y,Sun DD,Yuan LJ,et al.Clinical Application of Superior Vena Cava Spectra in Evaluation of Pulmonary Hypertension:A Comparative Echocardiography and Catheterization Study[J].Ultrasound Med Biol,2016,42(1):110-117.
[14]徐志伟,赵文强,程志祥.慢性肺源性心脏病患者血N末端B型钠尿肽和超敏C反应蛋白水平的临床意义[J/CD].中西医结合心血管病电子杂志,2015,3(33):69-70,72.
[15]赖蓉,李多,兰四友,等.法舒地尔联合无创正压通气治疗慢性肺源性心脏病急性加重的临床价值[J].中国现代医学杂志,2016,26(2):55-59.
[16]丁明霞,卢丹,常媛媛,等.低分子肝素治疗老年慢性阻塞性肺疾病合并肺心病急性发作期效果[J].临床肺科杂志,2015,20(3):487-489.
[17]王建雄,谢言秋,彭沪,等.丹参酮ⅡA磺酸钠注射液治疗老年肺源性心脏病患者的临床观察[J].中华老年心脑血管病杂志,2015,17(5):532-533.
[18]苟连平,刘世平,方志远.心脑欣丸对肺心病合并冠心病患者CAT评分及心肺功能、血液流变学的影响[J].中国药房,2016,27(20):2810-2813.
[19]邓俊,邓欢,冯健,等.氯沙坦与环磷腺苷葡胺联合治疗对肺心病患者肺功能与免疫功能的影响[J].中国老年学杂志,2016,36(8):1915-1917.
[20]胡晓冬,顾培洁.益气补肾化痰祛瘀法在改善缓解期慢性阻塞性肺疾病合并肺心病患者生存质量中的应用[J].湖北中医药大学学报,2015,17(4):55-57.
[21]Selman L,Mc Dermott K,Donesky D,et al.Appropriateness and acceptability of a Tele-Yoga intervention for people with heart failure and chronic obstructive pulmonary disease:qualitative findings from a controlled pilot study[J].BMC Complement Altern Med,2015,15:21.
[22]杜宋耿,陈德俊,陈尊发.低分子肝素钠注射液对肺心病患者纤维蛋白原、血小板颗粒膜蛋白和D-二聚体的影响[J].疑难病杂志,2015,14(3):230-232.
[23]袁连方,戴璇.红花黄色素对肺心病患者血小板CD62P表达、血浆D-dimer水平的影响及意义[J].山东医药,2015,55(28):86-87.
[24]郑咏仪,郑国雄,杨陪.老年充血性心衰与肺心病患者动脉血气和N末端脑钠肽及血小板参数的变化及意义[J].中国老年学杂志,2015,35(14):3898-3899.
[25]孙晓坤.应用Bi PAP无创呼吸机治疗肺心病并发Ⅱ型呼吸衰竭的临床效果观察[J].临床肺科杂志,2015,20(3):550-552.